Figure 1.

Decreased metabolic capacity of FMO3 (△), as indicated as percent free trimethylamine (TMA, ●) to total trimethylamine (○) excreted in the urine, in relation to menstruation. Filled boxes indicate the period of menstruation. Total urinary trimethylamine and free trimethylamine concentrations were calculated as mmol trimethylamine (TMA)/mol creatinine. Cases (A) and (B) were self-reported subjects suffering from malodour genotyped for homozygotic inactive Arg500stop FMO3 and homozygotic common [Glu158Lys; Glu308Gly] FMO3, respectively. Cases (C) and (D and E) were control subjects genotyped as heterozygotic for [Glu158Lys; Glu308Gly] FMO3 and homozygotic for wild FMO3, respectively.